NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2080221000

Registered date:10/02/2010

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedType 2 Diabetes Mellitus
Date of first enrollment10/02/2010
Target sample size
Countries of recruitment
Study typeInterventional
Intervention(s)investigational material(s) Generic name etc : Dapagliflozin INN of investigational material : Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational material : 10mg, oral, once daily

Outcome(s)

Primary Outcome
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteria- Already on voglibose treatment with a steady dosage for at least 8 weeks - Provision of informed consent prior to any study specific procedures - Diagnosed with type 2 diabetes
Exclude criteria- Having clinically relevant medical history or concurrent disease such as cardiovascular disease, renal disease, retinopathy, hepatic disease and haematological disease. - The investigator(s) judged that the Subject should not participate in the study according to screening test or medical history.

Related Information

Contact

Public contact
Name
Address RD-clinical-information-Japan@astrazeneca.com
Telephone
E-mail
Affiliation AstraZeneca KK
Scientific contact
Name
Address
Telephone
E-mail
Affiliation